A multicenter, phase III, double-blind clinical trial on 180 patients with histological diagnosis of NAFLD/NASH with or without hepatitis C demonstrated that treatment with a silybin–vitamin E–phosphatidylcholine complex for 12 months supported improvement of transaminase and γ-GT levels, along with improvement of insulin sensitivity. The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.